WallStSmart

Insmed Inc (INSM)vsMoolec Science SA Ordinary Shares (MLEC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 7642% more annual revenue ($606.42M vs $7.83M). MLEC leads profitability with a 0.0% profit margin vs -2.1%. MLEC earns a higher WallStSmart Score of 41/100 (D).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

MLEC

Hold

41

out of 100

Grade: D

Growth: 5.0Profit: 3.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -1.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

MLEC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-3.7410/10

Conservative balance sheet, low leverage

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

MLEC4 concerns · Avg: 3.5/10
Price/BookValuation
9.5x4/10

Trading at 9.5x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.37M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : MLEC

The strongest argument for MLEC centers on Debt/Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : MLEC

The primary concerns for MLEC are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while MLEC is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

MLEC is growing revenue faster at 9.5% — sustainability is the question.

MLEC generates stronger free cash flow (-30M), providing more financial flexibility.

Bottom Line

MLEC scores higher overall (41/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Moolec Science SA Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.

Visit Website →

Want to dig deeper into these stocks?